Interface Biologics Employee Directory
Biotechnology ResearchOntario, Canada11-50 Employees
Interface Biologics is a privately held, commercially oriented biotechnology company. Based in Toronto, Ontario, it develops biomedical polymer technologies designed to improve the safety and performance of medical devices. Its work centers on anti-thrombogenic additives to reduce clotting in blood-contacting devices and on polymers used in drug-delivery systems. The company serves medical device manufacturers and pharmaceutical developers seeking safer, more effective polymer solutions. In 2019, Interface Biologics completed a sale of Endexo surface modification assets to Evonik. In 2018, Kelley Dealhoy was named Vice President of Business Development.